ORIGINAL RESEARCH



Swimming emissions from dogs treated with spot-on fipronil or imidacloprid: Assessing the environmental risk

Rosemary Perkins¹ | Gaëtan Glauser² | Dave Goulson¹

¹School of Life Sciences, University of Sussex, Brighton, UK

²Neuchâtel Platform of Analytical Chemistry, University of Neuchâtel, Neuchâtel, Switzerland

Correspondence

Rosemary Perkins, School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK. Email: rp442@sussex.ac.uk

Funding information

Veterinary Medicines Directorate

Abstract

Background: Fipronil and imidacloprid are increasingly recognised as contaminants of concern in aquatic environments. This study aimed to quantify swimming emissions from dogs treated with spot-on fipronil or imidacloprid, assess the associated environmental risks and evaluate whether current label instructions on swimming restrictions are adequate.

Methods: Emissions from swimming were measured for 49 dogs treated with spot-on fipronil or imidacloprid on days 5, 14 or 28 post-application. The environmental risk was assessed by calculating risk quotients, dividing the predicted environmental concentrations by the predicted no-effect concentrations for freshwater ecosystems.

Results: Mean washoff ranged from 4% to 0.4% of the applied dose for fipronil and 10% to 1.4% for imidacloprid across the 5–28-day period. Risk quotients indicate a risk to aquatic ecosystems throughout the products' duration of action

Limitations: The results may underestimate emissions for fipronil, as swimming is permitted from 3 days post-application and measurements began on day 5.

Conclusion: This study highlights clear ecological risks from spot-on parasiticides and provides evidence that current label instructions on swimming do not provide sufficient environmental protection. Risk-based parasite control strategies and extended swimming restrictions are recommended. Regulatory review of environmental risk assessments and mitigation measures is warranted to protect aquatic environments.

INTRODUCTION

Fipronil and imidacloprid are potent insecticides widely used for the treatment and prevention of fleas on cats and dogs and are typically applied as monthly spot-on treatments. Originally developed for crop protection in the late 1980s and early 1990s, 2,3 their agricultural use is now heavily restricted in the European Union (EU) and UK due to environmental concerns, particularly regarding their adverse effects on pollinators. As persistent, mobile and toxic (PMT) chemicals, they are increasingly recognised as emerging contaminants of concern for aquatic ecosystems, and potentially for human health, 6-8 with several studies demonstrating the degradation of aquatic communities associated with exposure to these compounds. 8-12

Recent reports reveal widespread fipronil and imidacloprid contamination of fresh waters in the UK

despite restrictions on agricultural use, frequently occurring at concentrations that ecotoxicity studies have shown can harm aquatic life. 13-15 These findings have prompted scrutiny of the role of pet parasiticides in the measured pollution and of the regulatory framework governing their use. 16 New research has shown that 'down-the-drain' household transfer from treated pets, and subsequent entry via wastewater, is a major source of fipronil and imidacloprid freshwater pollution.¹⁷ High concentrations and strong positive correlations with dog swimming activity have also been demonstrated in dog swimming ponds, indicating that dog swimming is a further source of surface water pollution.¹⁸ However, little is known about swimming emissions from individual treated dogs, or the overall contribution of this pathway to surface water pollution, to help inform responsible prescribing practices and evidence-based mitigation strategies.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). Veterinary Record published by John Wiley & Sons Ltd on behalf of British Veterinary Association.

Vet Rec. 2025;e5560.

2 of 7 VETERINARY RECORD

Under the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicine Products (VICH) framework, environmental risk assessments for veterinary medicines used in non-food animals assume negligible environmental exposure. Consequently, no phase II risk assessment, requiring emissions and ecotoxicity data, is typically required prior to regulatory approval. ¹⁹ In light of recent research indicating widespread freshwater pollution from pet parasiticides, regulators in the EU and UK have concluded that the current approach should be reviewed. ^{20,21}

In 2011, the European Medicines Agency published a reflection paper on risk mitigation measures for veterinary medicinal products, recognising the potential for emissions via dog swimming. As a precaution, the paper recommended a minimum 48-hour interval between topical application of parasiticides and access to waterbodies for treated dogs. However, this default interval is not based on product-specific scientific data.²¹

A targeted phase II environmental risk assessment for dog swimming was conducted for Advocate Spoton Solution (Elanco, containing moxidectin and imidacloprid). This assessment calculated a predicted environmental concentration (PEC), based on the assumption that the full dose for the maximum size pipette enters a waterbody of 100 m³, and concluded that imidacloprid poses no significant risk to aquatic species. However, a 4-day swimming restriction was advised to mitigate risks associated with moxidectin.²² Notably, this assessment used a safe environmental threshold, or predicted no-effect concentration (PNEC), of 850,000 ng/L for imidacloprid several orders of magnitude higher than current PNEC estimates.^{23,24} The original PNEC was derived from ecotoxicity studies on the water flea Daphnia magna,²⁵ a test species now known to exhibit unusually high tolerance to imidacloprid. 26,27 Further detail on the methodology used to derive this PNEC is provided in the Supporting Information.

In this study, we hypothesise that fipronil and imidacloprid swimming emissions from spot-on treated dogs pose a risk to aquatic ecosystems throughout the product's duration of action and that label instructions on minimum waiting intervals before swimming do not provide adequate environmental protection. To test this hypothesis, we measured fipronil and imidacloprid swimming emissions from spot-on treated dogs on days 5, 14 and 28 post-application and assessed the environmental risk posed by these emissions through the calculation of risk quotients.

METHODS

Sample collection

Forty-nine dogs were volunteered by their owners; only healthy dogs that had not been treated with a parasiticide product containing fipronil or imidacloprid within the preceding 3 months were eligible for

inclusion. All the animals received a general health and weight check from a veterinarian prior to spot-on application. Twenty-five dogs were treated with Frontline Spot-on Dog 10% (w/v) (Boehringer Ingelheim, containing 67-402 mg fipronil, depending on the size of dog to be treated) and 24 dogs were treated with Advocate Spot-on Solution (Elanco, containing 40-400 mg imidacloprid and moxidectin), following the manufacturers' guidelines on dosage and application (see Supporting Information). After treatment, dogs returned on days 5, 14 or 28 post-application for sample collection. Dogs were placed in a plastic tub of water at approximately mid-shoulder depth (range 37-414 L) at a temperature of 20°C (within the normal range for inland water in the UK²⁶) for approximately 5 minutes to simulate swimming. All samples were analysed for both imidacloprid and fipronil controls—namely, imidacloprid-treated dogs were controls for fipronil-treated dogs and vice versa. Following swimming, the volume of water in the tub was measured using a combination of pre-applied calibration markings on the collecting tub (measured to the litre) and a volumetric 1 L beaker (measured to the nearest 100 mL).

Samples were collected in 15 mL lightsafe polypropylene Falcon tubes and stored at -20°C prior to being sent by express air shipment (also frozen) to Neuchâtel Platform of Analytical Chemistry, University of Neuchâtel, Switzerland, for analysis. The tub was cleaned with detergent and ethanol wipes between sampling events, and four replicate equipment blanks were taken. The extraction and analysis of imidacloprid and fipronil were performed according to Perkins et al.¹⁷ Detailed information on the methodology is available in the Supporting Information.

Statistical analyses to assess the effect of time on washoff were performed using Box–Cox transformed linear regression. All analyses were performed and all figures were created using R Studio software (version 1.2.5042-1).

Calculation of emissions through swimming and environmental risk assessment

Emissions were calculated as mass washoff and washoff percentage per dog based on measured concentrations of active ingredient (AI), where:

Mass washoff (mg) = Rinsate volume (L)

$$\times$$
 AI concentration (mg/L) (1)

Washoff percentage =
$$\frac{100 \times \text{mass washoff (mg)}}{\text{mass applied per dog (mg)}}$$
(2)

To assess the environmental risk posed by treated dogs entering waterbodies, PECs were calculated VETERINARY RECORD 3 of 7




FIGURE 1 Mean washoff percentages for fipronil and imidacloprid from spot-on treated dogs on days 5, 14 and 28 post-application through swimming, displayed as a percentage of the applied mass. Individual dogs were only washed on one occasion (i.e., washes were not sequential). Error bars indicate 95% confidence intervals. The *Y*-axis is square root transformed.

based on mean washoff percentages at days 5, 14 and 28 post-application, for a 45 kg dog treated with 400 mg imidacloprid or 534 mg fipronil (Tables S1 and S2) entering a $100~\text{m}^3$ ($10~\text{m} \times 10~\text{m} \times 1~\text{m}$ deep, 100,000~L) waterbody, based on the PEC calculation in the phase II assessment performed for Advocate. Based on previous related studies and risk assessments, the assumption was made that the AI dispersed evenly throughout the waterbody and the entire AI dose was administered. 17,22

Risk was assessed using risk quotients, which were calculated by dividing the PEC by the PNEC. The PNEC is the maximum concentration of a chemical in the environment below which no harmful effects are expected in an ecosystem. PNECs are derived using various methods, with the choice depending on the availability and quality of ecotoxicity data. The most widely used approach is the assessment factor method, which applies assessment factors to ecotoxicological data from the most sensitive species. These factors (typically between 1 and 100) help extrapolate findings from laboratory tests, single-species studies and short-term experiments to predict realworld ecosystem effects. Given that PNECs reflect the current state of knowledge, they should be reviewed regularly.^{28,29}

As PNECs can vary depending on their derivation and source, a range were used here: 6.8 ng/L and 0.77 ng/L for imidacloprid and fipronil, respectively, representing the lowest PNEC in freshwater sourced from the NORMAN Association in December 2024,²⁵ as well as PNECs of 4.8 ng/L for imidacloprid and 12.1 ng/L for fipronil, from European Chemicals Agency biocide assessments.^{23,30} The methods

used to derive the PNECs included in this analysis are described in the Supporting Information.

Risk quotients were interpreted in line with the phase II environmental risk assessment for veterinary medicines, with less than 1 indicating no risk and greater than 1 indicating a risk.³¹

To assess total emissions from the dog population through swimming and compare this to down-the-drain emissions described elsewhere, ¹⁷ population emission fractions (PEFs), defined as the percentage of total applied AI emitted via a defined pathway from a population, were estimated by modelling swimming emission results together with survey data on the reported frequency of swimming. ³² Estimation of the PEF was performed according to Perkins et al. ¹⁷ Detailed information on the methodology is available in Table S3.

RESULTS

Swimming emissions

Fipronil and imidacloprid were detected in 100% of swimming samples from treated dogs, with mean washoff percentages of 4.0%, 0.8% and 0.4% for fipronil and 10.1%, 1.8% and 1.4% for imidacloprid on days 5, 14 and 28 post-application (Figure 1 and Table S4). Washoff decreased over time post-application (p < 0.01).

Imidacloprid and fipronil were detected in three of 25 and two of 24 of the swimming samples from reciprocal control dogs, respectively. The average mass washoff from untreated control dogs was less than

4 of 7 VETERINARY RECORD




FIGURE 2 Predicted environmental concentrations for a 45 kg dog treated with spot-on fipronil or imidacloprid entering a 100 m³ waterbody at 5, 14 and 28 days post-application, based on mean washoff percentages in this study. Square root transformed *Y*-axis. Dotted lines indicate predicted no-effect concentrations (safe thresholds) from European Chemicals Agency biocide assessments of 12.1 ng/L for fipronil and 4.8 ng/L for imidacloprid, ^{23,30} and dashed lines indicate predicted no-effect concentrations from the NORMAN Association of 0.77 ng/L for fipronil and 6.8 ng/L for imidacloprid. ²⁴

TABLE 1 Predicted environmental concentrations (PEC) and risk quotients for a 45 kg dog treated with spot-on fipronil or imidacloprid entering a 100 m³ waterbody 5, 14 and 28 days post-application, based on mean washoff percentages in this study.

	Day	PEC (ng/L)	Risk quotients based on PNECs	
Imidacloprid			ECHA (4.8 ng/L)	NORMAN (6.8 ng/L)
	5	404.0	84.2	59.4
	14	72.0	15.0	10.6
	28	56.0	11.7	8.2
Fipronil			ECHA (12.1 ng/L)	NORMAN (0.77 ng/L)
	5	213.6	17.6	277.4
	14	42.7	3.5	55.5
	28	21.3	1.7	27.7

Note: Risk quotients based on predicted no-effect concentrations (PNECs) from European Chemicals Agency (ECHA) biocides assessments 23,30 and NORMAN database. 24

2% of that observed in treated dogs for both compounds (Table S4), indicating that inadvertent contamination was unlikely to have influenced the study results. Neither compound was detected in equipment blanks.

Predicted environmental concentrations

PECs and risk quotients are provided in Figure 2 and Table 1. PNECs were exceeded for both compounds following a single swimming event for at least 28 days following application (Figure 2).

Population emissions

Based on reported swimming frequency, population emission fractions (the proportion of total AI applied to the population emitted through swimming) were estimated at 0.8% and 1.4% for fipronil and imidacloprid, respectively. Total emissions through swimming were therefore lower than those occurring downthe-drain, which previous research has estimated to account for 6.0% of fipronil and 9.1% of imidacloprid applied in spot-on treatments to dogs.¹⁷

DISCUSSION

These results show that swimming emissions from dogs treated with spot-on fipronil or imidacloprid occur for at least 28 days after application, posing a risk to aquatic ecosystems throughout this period. These findings indicate that current datasheet guidelines, which permit swimming from 3 days after application of spot-ons containing fipronil and 5 days after spot-ons containing imidacloprid and moxidectin,³³ do not provide adequate environmental protection. Instead, the evidence suggests that treated dogs should not be allowed to enter waterbodies for the licensed duration of action of these products (4 weeks) to minimise the risk to aquatic ecosystems.

While the data indicate that overall emissions through swimming are lower than those occurring via down-the-drain pathways (e.g., bathing, bed washing and owner handwashing), localised impacts may still occur. Indeed, with spot-on treated dogs entering UK waterbodies more than 3 million times every year,³² there is considerable potential for direct parasiticide

VETERINARY RECORD 5 of 7

emissions through swimming, particularly in standing waterbodies entered by multiple dogs.

There are several potential strategies to effectively reduce swimming emissions from dogs treated with spot-on products. Previous research found that 86% of dog owners were unaware of the environmental risks associated with pet parasiticides, indicating considerable scope for improved product labelling and consumer awareness. 18 Transitioning from routine vear-round prophylaxis of small animal ectoparasites towards a risk-based approach that targets higher risk animals or confirmed infestations—as recommended by multiple British veterinary associations³⁴—would both reduce parasiticide emissions and help to mitigate other potential adverse consequences of overuse, such as resistance.³⁵ It should be noted that little is known about the environmental emissions and risks associated with alternative ectoparasiticide products, including the newer generation of systemic isoxazolines; however, the available evidence—including demonstration of fluralaner in swimming water following entry of an orally treated dog—indicates potential concerns. 36,37 Sales data indicating a shift towards isoxazolines in recent years^{32,36} highlight the urgent need for further research on the fate and impact of other pet parasiticides to avoid the occurrence of 'regrettable substitution', where hazardous products are replaced with alternatives that pose similar or greater risks.

Regulatory measures to mitigate fipronil and imidacloprid emissions could include advising extended swimming restrictions for spot-on treated dogs and restricting product availability, as many spot-on products containing fipronil and imidacloprid are available for general sales in the UK, with no requirement for a prescription from a veterinarian or other suitably qualified person.³⁸

Scientific understanding of the environmental and human health risks posed by novel chemicals is constantly evolving. Estimates of safe environmental thresholds can vary significantly based on the representation of sensitive species in datasets and the assessment factors applied. For newly introduced chemicals, aquatic ecotoxicity data are often limited to a few species, whereas river ecosystems may support hundreds.³⁹ This creates uncertainty, potentially leading to either under- or overprotection.²⁹ To address such uncertainties, pesticides used in plant protection products in the UK require reassessment and reapproval every 15 years.40 However, no similar review process exists for veterinary medicines. The inclusion of an imidacloprid PNEC significantly higher than currently recognised thresholds in the phase II environmental risk assessment for Advocate Spot-on Solution^{22,23,24} underscores the need for regular reassessment of environmental risks, particularly for intrinsically hazardous compounds such as parasiticides.

The interpretation of risk quotients within the VICH framework may also warrant reconsideration. Currently, a binary approach is applied, where a risk

quotient of less than 1 indicates no risk, while greater than 1 signifies the presence of risk. ³¹ However, adopting a staged risk ranking system (e.g., low, medium, high), as proposed elsewhere, ^{40–42} could offer a more nuanced and realistic assessment. This is particularly relevant for parasiticides, which are often used on a large scale, have multiple potential environmental exposure pathways, and for which some degree of risk cannot be entirely excluded.

The samples in this study were collected starting 5 days post-application, following datasheet guidelines that advise against swimming for 4 days after applying Advocate spot-on. This sampling timeframe may have led to an underestimation of washoff emissions for fipronil-based products, for which swimming is permitted from 3 days post-application. Previous research has indicated a rapid decline in spot-on emissions during the initial days following application, which the PEF estimated here may not reflect.^{27,43}

Our findings highlight gaps in the current regulatory framework and usage guidelines for spot-on parasiticide products. Improving product labelling, restricting access (e.g., to prescription-only status), raising consumer awareness and transitioning to risk-based or reactionary parasite treatment can help to mitigate these emissions and promote more sustainable companion animal parasite control practices.

AUTHOR CONTRIBUTIONS

Rosemary Perkins and Dave Goulson conceived and designed the study. Rosemary Perkins collected the data, analysed the data, prepared figures and tables and wrote the manuscript. Gaetan Glauser performed the chemical analysis and created the protocol for chemical extraction. All the authors were involved in manuscript writing.

ACKNOWLEDGEMENTS

The authors wish to give special thanks to the study participants who generously volunteered their time and their dogs to participate in this study. We would also like to thank the staff at Chipping Norton Veterinary Hospital for their valuable assistance with the research. This work was supported by the Veterinary Medicines Directorate, who assisted with the review of the draft manuscript.

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available in the Supporting Information.

ETHICS STATEMENT

The study protocol was approved by the University of Sussex Animal Welfare and Ethical Review Body (reference ARG-27/AWERB-68), and an Animal

Test Certificate Type-S (reference 00733/2021) was issued by the Veterinary Medicines Directorate in accordance with Veterinary Medicines Regulations. Participating dog owners gave written consent prior to enrolment in the study.

REFERENCES

- 1. Rust MK. Advances in the control of *Ctenocephalides felis* (cat flea) on cats and dogs. Trends Parasitol. 2005;21(5):232–36.
- 2. Krämer F, Mencke N. Flea biology and control. Heidelberg: Springer Berlin Heidelberg; 2001. p. 63–64.
- 3. Tingle CCD, Rother JA, Dewhurst CF, Lauer S, King WJ. Fipronil: environmental fate, ecotoxicology, and human health concerns. Rev Environ Contam Toxicol. 2003;176:1–66.
- European Commission. Commission Implementing Regulation (EU) 2018/783 of 29 May 2018 amending Implementing Regulation (EU) No 540/2011 as regards the conditions of approval of the active substance imidacloprid. Off J Eur Union. 2018;132(31). Available from: https://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=CELEX%3A32018R0783
- European Commission. European Commission Implementing regulation (EU) No 485/2013 of 24 May 2013 amending Implementing Regulation (EU) No 540/2011, as regards the conditions of approval of the active substances clothianidin, thiamethoxam and imidacloprid. Off J Eur Union. 2013;139(2). Available from: https://eur-lex.europa.eu/eli/reg_impl/2013/485/oj
- 6. Hale SE, Neumann M, Schliebner I, Schulze J, Averbeck FS, Castell-Exner C, et al. Getting in control of persistent, mobile and toxic (PMT) and very persistent and very mobile (vPvM) substances to protect water resources: strategies from diverse perspectives. Environ Sci Eur. 2022;34(1):22.
- 7. Zhou J, Zuo S, Wang Y, An R, Zheng S, Cao L, et al. Prioritization of risks posed by synthetic chemicals manufactured in China toward humans and the environment via persistence, bioaccumulation, mobility and toxicity properties. Environ Int. 2023;178:108042.
- 8. Merga LB, Van den Brink P. Ecological effects of imidacloprid on a tropical freshwater ecosystem and subsequent recovery dynamics. Sci Total Environ. 2021;784:147167.
- Van Dijk TC, Van Staalduinen MA, Van der Sluijs JP. Macroinvertebrate decline in surface water polluted with imidacloprid. PLoS One. 2013;8(5):e62374.
- 10. Hayasaka D, Korenaga T, Suzuki K, Saito F, Sánchez-Bayo F, Goka K. Cumulative ecological impacts of two successive annual treatments of imidacloprid and fipronil on aquatic communities of paddy mesocosms. Ecotoxicol Environ Saf. 2012;80:355–62.
- 11. Macaulay S, Hageman K, Piggott J, Noël P, Matthaei CD. Warming and imidacloprid pulses determine macroinvertebrate community dynamics in experimental streams. Glob Chang Biol. 2021;27(21):5469–90.
- 12. Miller JL, Schmidt TS, Van Metre PC, Mahler BJ, Sandstrom MW, Nowell LH, et al. Common insecticide disrupts aquatic communities: a mesocosm-to-field ecological risk assessment of fipronil and its degradates in U.S. streams. Sci Adv. 2020;6(43):eabc1299.
- 13. Egli M, Rapp-Wright H, Oloyede O, Francis W, Preston-Allen R, Friedman S, et al. A One-Health environmental risk assessment of contaminants of emerging concern in London's waterways throughout the SARS-CoV-2 pandemic. Environ Int. 2023;180:108210.
- Perkins R, Whitehead M, Civil W, Goulson D. Potential role of veterinary flea products in widespread pesticide contamination of English rivers. Sci Total Environ. 2021;750(1):143560.
- 15. Spurgeon D, Wilkinson H, Civil W, Hutt L, Armenise E, Kieboom N, et al. Worst-case ranking of organic chemicals detected in groundwaters and surface waters in England. Sci Total Environ. 2022;835:155101.
- European Medicines Agency. Reflection paper on the environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs [Internet]. 2023.

- Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-environmental-risk-assessment-ectoparasiticidal-veterinary-medicinal-products-used-cats-and-dogs_en.pdf
- Perkins R, Barron L, Glauser G, Whitehead M, Woodward G, Goulson D. Down-the-drain pathways for fipronil and imidacloprid applied as spot-on parasiticides to dogs: estimating aquatic pollution. Sci Total Environ. 2024;917: 170175
- 18. Yoder LE, Egli M, Richardson AK, Brooker A, Perkins R, Collins CMT, et al. Dog swimming and ectoparasiticide water contamination in urban conservation areas: a case study on Hampstead Heath, London. Sci Total Environ. 2024;955:176686.
- 19. European Medicines Agency. Guideline on environmental impact assessment (EIAS) for veterinary medicinal products—phase I. CVMP/VICH/592/98-FINAL. VICH Topic GL 6 (exociticity phase I). 2000:4. Available from: https://www.ema.europa.eu/en/documents/scientificguideline/vich-gl6-environmental-impact-assessment-eiasveterinary-medicinal-products-phase-i-step-7_en.pdf
- Veterinary Medicines Directorate. Pharmaceuticals in the environment (PiE) [Internet]. 2024 [cited 2024 Aug 12]. Available from: https://www.vmdconnect.uk/the-environment
- European Medicines Agency. Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products. Vol. 44. 2012. p. 1–10. https://www.ema.europa.eu/en/documents/scientificguideline/reflection-paper-risk-mitigation-measures-related-environmental-risk-assessment-veterinary-medicinal-products_en.pdf
- European Medicines Agency. Advocate (imidacloprid & moxidectin). Scientific Discussion. CVMP/0297/03 [Internet]. Vol. 44. 2009. Available from: https://medicines.health.europa.eu/veterinary/en/documents/download/166fe003-5e48-4965-879b-a52cd858d970
- 23. European Chemicals Agency. Directive 98/8/EC concerning the placing of biocidal products on the market [Internet]. 2011. Available from: https://echa.europa.eu/information-on-chemicals
- NORMAN. NORMAN ecotoxicology database. Accessed Nov 2024. 2024. Available from: https://www.norman-network. com/nds/ecotox/
- Veterinary Medicines Directorate. Freedom of information request ATI0731. 2021.
- 26. Hannah DM, Garner G. River water temperature in the United Kingdom: changes over the 20th century and possible changes over the 21st century. Prog Phys Geogr. 2015;39(1):68–
- 27. Teerlink J, Hernandez J, Budd R. Fipronil washoff to municipal wastewater from dogs treated with spot-on products. Sci Total Environ. 2017;599–600:960–66.
- NORMAN. Deriving environmental quality standards for chemical substances in surface waters [Internet]. 2024 [cited 2024 Dec 10]. Available from: https://www.norman-network. com/nds/ecotox/docs/Fact-sheet-EQS-Derivation.pdf
- 29. Whitehouse P, Crane M, Grist E, Hagan AO, Sorokin N. Derivation and expression of water quality standards: opportunities and constraints in adopting risk-based approaches in EQS setting. R&D Technical Report P2-157/TR. 2004. p. 120. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/290412/sp2-157-tr-e-e.pdf
- European Chemicals Agency. Directive 98/8/EC concerning the placing biocidal products on the market [Internet]. 2015. Available from: https://echa.europa.eu/documents/10162/225b9c58-e24c-6491-cc8d-7d85564f3912
- 31. European Medicines Agency. VICH GL 38 (ecotoxicity phase II). 2004. :0–9. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl38-environmental-impact-assessments-veterinary-medicinal-products-vmps-phase-ii_en.pdf
- 32. Perkins R, Goulson D. To flea or not to flea: survey of UK companion animal ectoparasiticide usage and activities affecting pathways to the environment. PeerJ. 2023;11:15561.

VETERINARY RECORD 7 of 7

33. National Office of Animal Health (NOAH). Datasheets [Internet]. 2022 [cited 2022 Aug 11]. Available from: https://www.noahcompendium.co.uk/?id=-4943

- 34. British Veterinary Association. BVA, BSAVA and BVZS policy position on responsible use of parasiticides for cats and dogs [Internet]. 2021. Available from: https://www.bva.co.uk/media/4352/bva-bsava-and-bvzs-policy-position-on-responsible-use-of-parasiticides-for-cats-and-dogs.pdf
- 35. BSAVA. Antiparasiticide resistance. In: Nind F, Mosedale P, editors. BSAVA guide to the use of veterinary medicines [Internet]. 2022. p. 92–94. Available from: https://www.bsavalibrary.com/docserver/fulltext/10.22233/9781905319862/BSAVA_Medicine_Guide_2_9781905319862. 20.92-94.pdf?expires=1737032446&id=id&accname= guest&checksum=2D11DC9BA9989F9DD78EC52DF273C364
- 36. Wells C, Collins CMT. A rapid evidence assessment of the potential risk to the environment presented by active ingredients in the UK's most commonly sold companion animal parasiticides. Environ Sci Pollut Res Int. 2022;29(30):45070–88.
- 37. Diepens NJ, Belgers D, Buijse L, Roessink I. Pet dogs transfer veterinary medicines to the environment. Sci Total Environ. 2023;858:159550.
- 38. Veterinary Medicines Directorate. Product information database [Internet]. 2020 [cited 2020 Jan 23]. Available from: https://www.vmd.defra.gov.uk/ProductInformationDatabase/Default.aspx
- 39. Morrissey CA, Mineau P, Devries JH, Sanchez-Bayo F, Liess M, Cavallaro MC, et al. Neonicotinoid contamination of global surface waters and associated risk to aquatic invertebrates: a review. Environ Int. 2015;74:291–303.
- 40. Health and Safety Executive. Approval to use an active substance in a pesticide [Internet]. 2025 [cited 2025 Mar 23]. Available from: https://secure.pesticides.gov.uk/pestreg/

- 41. Palma P, Köck-Schulmeyer M, Alvarenga P, Ledo L, Barbosa IR, López de Alda M, et al. Risk assessment of pesticides detected in surface water of the Alqueva reservoir (Guadiana basin, southern Portugal). Sci Total Environ. 2014;488–489:208–219.
- 42. Zhao JL, Ying GG, Liu YS, Chen F, Yang JF, Wang L, et al. Occurrence and a screening-level risk assessment of human pharmaceuticals in the pearl river system, South China. Environ Toxicol Chem. 2010;29(6):1377–84.
- 43. Dyk MB, Liu Y, Chen Z, Vega H, Krieger RI. Fate and distribution of fipronil on companion animals and in their indoor residence following spot-on flea treatments. J Environ Sci Health B. 2012;47(10):913–24.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Perkins R, Glauser G, Goulson D. Swimming emissions from dogs treated with spot-on fipronil or imidacloprid: Assessing the environmental risk. Vet Rec. 2025;e5560. https://doi.org/10.1002/vetr.5560